PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar goshaw (45.73) Submitted: 3/2/2011 11:35:11 PM : Outperform Start Price: $5.18 PDLI Score: +25.39

Q

Featured Broker Partners


Advertisement